Article

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants

2026-03-16

Abstract excerpt

<title>Abstract</title> <p>The treatment of urothelial cancer (UC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICIs). However, while ICIs have achieved better therapeutic results than traditional chemotherapeutic agents, immune-related adverse events (irAEs) can lead to poor treatment outcomes. This exploratory study was designed to seek tumour single-nucleotide polymorphisms (SNP...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b7a0bfa4-d09d-567a-a8e0-51e7222bc6b7
DOI: 10.21203/rs.3.rs-8919966/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variantsDOI 10.21203/rs.3.rs-8919966/v1Read

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.Semantic proximity Read

Polygenic Risk for Skin Autoimmunity Impacts Immune Checkpoint Blockade in Bladder CancerSemantic proximity Read

Single-Nucleotide Polymorphisms (SNPs) Can Predict the Efficacy and Toxicity of Cancer Immunotherapy? A Systematic ReviewSemantic proximity Read

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.Semantic proximity Read

The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.Semantic proximity Read

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohortSemantic proximity Read

CTLA4 genetic variants associated with urothelial bladder cancer susceptibilitySemantic proximity Read

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Semantic proximity Read

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.Semantic proximity Read

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read

Distribution of PD-1.5 Gene Variant (rs2227981): A Possible Approach for Risk Assessment in Bladder Cancer.Semantic proximity Read

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitisSemantic proximity Read